This story was up to date at 8:35 p.m.
April 23, 2021 — Use of the Johnson & Johnson COVID-19 vaccine ought to resume in the US for all adults, the FDA and CDC mentioned Friday, though well being care suppliers ought to warn sufferers of the chance of growing the uncommon and severe blood clots that induced the businesses to pause the vaccine’s distribution earlier this month.
“What we’re seeing is the general charge of occasions was 1.9 instances per million individuals. In girls 18 to 29 years there was an approximate 7 instances per million. The chance is even decrease in girls over the age of fifty at .9 instances per million,” CDC Director Rochelle Walensky, MD, mentioned in a information briefing Friday night..
Ultimately, the potential advantages of the vaccine far outweighed its dangers.
“When it comes to advantages, we discovered that for each 1 million doses of this vaccine, the J&J vaccine may forestall over 650 hospitalizations and 12 deaths amongst girls ages 18-49,” Walensky mentioned. The potential advantages to girls over 50 had been even higher: It may forestall 4700 hospitalizations and 650 deaths.
“Ultimately, this vaccine was proven to be secure and efficient for the overwhelming majority of individuals,” Walensky mentioned at a press briefing on Friday night time.
The advice to proceed the vaccine’s rollout got here barely 2 hours after a CDC Advisory Committee on Immunization Practices voted to advocate the pause be lifted. The vote was 10-4 with one abstention.
The choice additionally consists of directions for the warning directed at girls beneath 50 who’ve an elevated danger of a uncommon however severe blood clot dysfunction referred to as thrombosis with thrombocytopenia syndrome (TTS).
As of April 21, 15 instances of TTS, all in girls and 13 of them in girls beneath 50, have been confirmed amongst 7.98 million doses of the J&J vaccine administered within the U.S. Three girls have died.
The FDA and CDC really useful the pause on April 13 after studies that 6 girls developed a blood clotting dysfunction 6 to 13 days after they obtained the J&J vaccine.
William Schaffner, MD, an infectious illness knowledgeable at Vanderbilt College in Nashville, and a non-voting ACIP member, mentioned in an interview the panel made the appropriate advice.
He applauded each the choice to restart the vaccine and the up to date warning data that “will clarify [TTS] extra totally to individuals, notably girls, who’re coming to be vaccinated.”
As to girls within the danger group needing to have a alternative of vaccines, Schaffner mentioned that will probably be addressed in a different way throughout the nation.
“Each supplier is not going to have different vaccines of their location so there will probably be many various methods to do that. You’ll have to get this data and choose which web site you’re going to relying on which vaccine is out there if this matter is essential to you,” he famous.
ACIP made right this moment’s resolution after a 6-hour emergency assembly to listen to proof on advantage of Johnson & Johnson’s protecting advantages towards COVID-19 vs. danger of TTS.
Within the CDC-FDA press briefing, Walensky identified that over the previous few days, as regulators have reviewed the uncommon occasions, newly recognized sufferers had been handled appropriately, with out using heparin, which isn’t suggested for treating TTS.
Because of this, regulators felt like their messages had gotten out to docs who now knew take particular precautions when treating sufferers with the dysfunction.
She mentioned the Johnson & Johnson shot remained an essential choice as a result of it was handy to provide and simpler to retailer than the opposite vaccines at the moment approved within the U.S.
Peter Marks, MD, the director of FDA’s Heart for Biologics Analysis and Analysis, mentioned the company had already added data describing the chance of the uncommon clotting dysfunction to its reality sheets for sufferers and docs.
Janet Woodcock, performing commissioner of the FDA, mentioned vaccination facilities may resume giving the “one and finished” photographs as early as tomorrow morning.